Selective inhibition of 12-lipoxygenase protects islets and beta cells from inflammatory cytokine-mediated beta cell dysfunction
Autor: | Dieter Schmoll, Anton Simeonov, Ganesha Rai, Norine Kuhn, David J. Maloney, Jessica R. Weaver, Angela Dudda, Theodore R. Holman, Ajit Jadhav, David A. Taylor-Fishwick, Lindsey Glenn, Jerry L. Nadler |
---|---|
Rok vydání: | 2014 |
Předmět: |
Male
medicine.medical_specialty Cell Survival Endocrinology Diabetes and Metabolism medicine.medical_treatment Interleukin-1beta Inflammation Apoptosis Enzyme-Linked Immunosorbent Assay Pharmacology Biology In Vitro Techniques Arachidonate 12-Lipoxygenase Real-Time Polymerase Chain Reaction Proinflammatory cytokine Cell Line Mice Downregulation and upregulation Internal medicine Insulin-Secreting Cells Internal Medicine medicine Animals Humans 12-Hydroxy-5 8 10 14-eicosatetraenoic Acid Enzyme Inhibitors Beta (finance) Tumor Necrosis Factor-alpha Mice Inbred C57BL Cytokine Endocrinology Cell culture Tumor necrosis factor alpha medicine.symptom Beta cell |
Zdroj: | Diabetologia. 58(3) |
ISSN: | 1432-0428 |
Popis: | Islet inflammation leads to loss of functional pancreatic beta cell mass. Increasing evidence suggests that activation of 12-lipoxygenase leads to inflammatory beta cell loss. This study evaluates new specific small-molecule inhibitors of 12-lipoxygenase for protecting rodent and human beta cells from inflammatory damage. Mouse beta cell lines and mouse and human islets were treated with inflammatory cytokines IL-1β, TNFα and IFNγ in the absence or presence of novel selective 12-lipoxygenase inhibitors. Glucose-stimulated insulin secretion (GSIS), gene expression, cell survival and 12-S-hydroxyeicosatetraenoic acid (12-S-HETE) levels were evaluated using established methods. Pharmacokinetic analysis was performed with the lead inhibitor in CD1 mice. Inflammatory cytokines led to the loss of human beta cell function, elevated cell death, increased inflammatory gene expression and upregulation of 12-lipoxygenase expression and activity (measured by 12-S-HETE generation). Two 12-lipoxygenase inhibitors, Compounds 5 and 9, produced a concentration-dependent reduction of stimulated 12-S-HETE levels. GSIS was preserved in the presence of the 12-lipoxygenase inhibitors. 12-Lipoxygenase inhibition preserved survival of primary mouse and human islets. When administered orally, Compound 5 reduced plasma 12-S-HETE in CD1 mice. Compounds 5 and 9 preserved the function and survival of human donor islets exposed to inflammatory cytokines. Selective inhibition of 12-lipoxygenase activity confers protection to beta cells during exposure to inflammatory cytokines. These concept validation studies identify 12-lipoxygenase as a promising target in the prevention of loss of functional beta cells in diabetes. |
Databáze: | OpenAIRE |
Externí odkaz: |